Key Highlights
- MIRA Pharmaceuticals (NASDAQ:MIRA) reported a nine month net loss of USD 3,781,418 for 2026, against USD 4,459,164 a year earlier.
- Third quarter net loss widened to USD 1,422,732 from USD 1,137,673 as research spending more than doubled to USD 947,014.
- Cash and cash equivalents were about USD 2.5 million at September 30, 2026, with an accumulated Deficit of about USD 43.4 million.
- Management expects cash to fund operations into at least the first quarter of 2027, while targeting a Phase 2a start in the second quarter of 2027.
Nine Month Loss Narrows While the Quarter Moves the Other Way
MIRA Pharmaceuticals (NASDAQ:MIRA) filed its Quarterly Report for the period ended September 30, 2026 on November 16, 2026. The company is a clinical-stage drug developer with no revenue, focused on oral small-molecule treatments for chemotherapy-induced peripheral neuropathy, chronic inflammatory pain and obesity. Its three candidates are Ketamir-2, MIRA-55 and SKNY-1, the last added through the September 2025 Acquisition of a related-party company.
The nine month net loss was USD 3,781,418, down about USD 0.7 million from USD 4,459,164. The third quarter told a different story, with net loss rising USD 285,059 to USD 1,422,732 as spending shifted from administration to research.
Research Spending Doubles as Overhead Falls Sharply
General and administrative expenses fell to USD 465,014 in the quarter from USD 904,346, mostly on lower stock-based compensation of about USD 0.3 million and lower Payroll costs. Over nine months, the same line dropped USD 1.95 million to USD 1,494,042, with stock-based compensation accounting for USD 1.5 million of the decline.
Research and development expenses rose to USD 947,014 in the quarter from USD 412,639, and to USD 2,177,584 over nine months from USD 1,223,240. The filing attributes the increase to pre-IND work for MIRA-55 and SKNY-1 and protocol work for the Ketamir-2 Phase 2a study. Toxicology spending reached USD 258,500 in the quarter against USD 45,487, and research costs reached USD 536,050.
The Equity stake in a related-party Nasdaq-listed company added to the pressure. The share of that investee's losses was USD 215,233 over nine months, against a gain of USD 176,056 a year earlier. Interest income rose to USD 106,580 from USD 45,741.
A Thin Cash Balance Meets a Going Concern Warning
Cash and cash equivalents were about USD 2.5 million at quarter end, after cash used in operations of USD 3,705,874 over nine months. Financing activities were a net outflow of USD 136,416 in the period, against an inflow of USD 3,335,240 a year earlier. Calculated from the cash flow statement, the net change in cash was a decline of USD 3,842,290.
The filing states that cash on hand is insufficient to support operations for at least 12 months after issuance of the statements, which raises substantial doubt about continuing as a going concern. Management expects the current balance to last into at least the first quarter of 2027 and points to debt, Equity Financing and its at-the-market program as possible sources. The accumulated deficit was about USD 43.4 million, and 42,022,087 shares were outstanding on November 13, 2026.
Where Things Stand
The answer from the filing is that funding is the open question. MIRA Pharmaceuticals (NASDAQ:MIRA) has about USD 2.5 million in cash, a nine month operating cash burn of USD 3,705,874, and a stated runway into at least the first quarter of 2027, which is before the targeted Phase 2a start in the second quarter of 2027. The nine month loss narrowed to USD 3,781,418 only because stock-based compensation fell, while research spending is climbing. Any new Capital would need to come from the at-the-market program or other financing described in the filing.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...